Blog

Research efforts exploring IO rechallenge after prior ICI exposure to understand its potential in mRCC – ASCO

Collage photo of Toni Choueiri, Nazli Dizman, Marc Machaalani and Emre Yekedüz

May 25, 2024, 04:57

Research efforts exploring IO rechallenge after prior ICI exposure to understand its potential in mRCC – ASCO

Toni Choueiri shared a post by ASCO on X/Twitter:

“Thank you ASCO Daily News for the opportunity to work on this topic with our wonderful team Nazli Dizman, Marc Machaalani, Emre Yekedüz!”

Quoting ASCO’s post:

“For ASCO Daily News, Toni Choueiri, Nazli Dizman, Marc Machaalani and Emre Yekedüz examine recent/ongoing research efforts exploring IO rechallenge after prior ICI exposure to understand its potential in mRCC.”

Research efforts exploring IO rechallenge after prior ICI exposure to understand its potential in mRCC - ASCO

Source: Toni Choueiri/X and ASCO/X

Toni Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School. He is the Medical Director of International Strategic Initiatives at Dana-Farber and past President of the Medical Staff at DFCI (2016-2018).

He received the George Canellos Award for Excellence in Clinical Investigation and Patient Care from DFCI in 2013, the Eugene Schonfeld Award from the Kidney Cancer Association (KCA) in 2016, and is a 2021 Giants of Cancer Care inductee. He serves on the National Comprehensive Cancer Network (NCCN) Kidney Cancer Panel, KidneyCan Board, the National Cancer Institute (NCI) GU Steering Committee, and is past Chairman (2015-2018) of the Medical and Scientific Steering Committee of the KCA.

Dr. Choueiri is an elected member of the American Society of Clinical Investigation (ASCI). In addition, he is an Aresty Scholar from the Wharton School of Business at the University of Pennsylvania.

The American Society of Clinical Oncology (ASCO) is a leading professional organization representing nearly 45,000 physicians and oncology specialists worldwide, dedicated to cancer care. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, ASCO is committed to advancing cancer research, education, prevention, and high-quality patient care.